PVLA
Palvella Therapeutics, Inc. (PVLA) reported net income of -$41.72M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$41.72M | -139.3% |
| FY 2024 | -$17.43M | -193.3% |
| FY 2023 | $18.69M | +156.2% |
| FY 2022 | -$33.28M | +27.2% |
| FY 2021 | -$45.74M | -22.9% |
| FY 2020 | -$37.23M | -46.2% |
| FY 2019 | -$25.47M | +4.8% |
| FY 2018 | -$26.75M | -51.6% |
| FY 2017 |
Palvella Therapeutics, Inc. (PVLA) reported net income of -$41.72M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2013 and fiscal 2025, Palvella Therapeutics, Inc.'s net income declined from $66.20K to -$41.72M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$17.65M |
| +22.6% |
| FY 2016 | -$22.80M | -62.2% |
| FY 2015 | -$14.06M | -42.7% |
| FY 2014 | -$9.85M | -14980.0% |
| FY 2013 | $66.20K | - |